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Abstract
Glaucoma is a leading cause of blindness worldwide. Primary open-angle glaucoma (POAG) is the most common subtype
and is a complex trait with multigenic inheritance. Genome-wide association studies have previously identified a significant
association between POAG and the SIX6 locus (rs10483727, odds ratio (OR) = 1.32, p = 3.87610211). SIX6 plays a role in ocular
development and has been associated with the morphology of the optic nerve. We sequenced the SIX6 coding and
regulatory regions in 262 POAG cases and 256 controls and identified six nonsynonymous coding variants, including five
rare and one common variant, Asn141His (rs33912345), which was associated significantly with POAG (OR= 1.27,
p = 4.2610210) in the NEIGHBOR/GLAUGEN datasets. These variants were tested in an in vivo Danio rerio (zebrafish)
complementation assay to evaluate ocular metrics such as eye size and optic nerve structure. Five variants, found primarily
in POAG cases, were hypomorphic or null, while the sixth variant, found only in controls, was benign. One variant in the SIX6
enhancer increased expression of SIX6 and disrupted its regulation. Finally, to our knowledge for the first time, we have
identified a clinical feature in POAG patients that appears to be dependent upon SIX6 genotype: patients who are
homozygous for the SIX6 risk allele (His141) have a statistically thinner retinal nerve fiber layer than patients homozygous for
the SIX6 non-risk allele (Asn141). Our results, in combination with previous SIX6 work, lead us to hypothesize that SIX6 risk
variants disrupt the development of the neural retina, leading to a reduced number of retinal ganglion cells, thereby
increasing the risk of glaucoma-associated vision loss.
Citation: Ulmer Carnes M, Liu YP, Allingham RR, Whigham BT, Havens S, et al. (2014) Discovery and Functional Annotation of SIX6 Variants in Primary Open-Angle
Glaucoma. PLoS Genet 10(5): e1004372. doi:10.1371/journal.pgen.1004372
Editor: Greg Gibson, Georgia Institute of Technology, United States of America
Received November 20, 2013; Accepted March 26, 2014; Published May 29, 2014
Copyright:  2014 Ulmer Carnes et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: ECO is a NARSAD young investigator. This work was supported by R01EY013315 (MAH), R01EY019126 (MAH), R01EY015543 (RRA), P30 EY005722 (Duke
Eye Center); EY015872, EY022305, (JLW); EY015473 and UO1 HG004728 (LRP) Harvard Glaucoma Center for Excellence, and the Margolis Fund (JLW and LRP);
Research to Prevent Blindness (JLW, LRP); EY015473 (LRP). A list of the GLAUGEN collaborators is found at The Primary Open-Angle Glaucoma Genes and
Environment (GLAUGEN) Study listing on dbGAP, study Accession: http://www.ncbi.nlm.nih.gov/gap/ ders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mike.hauser@duke.edu
. These authors contributed equally to this work.
" ECO and MAH also contributed equally to this work.
` Membership of NEIGHBORHOOD Consortium Investigators is provided in the Acknowledgments.
Introduction
Primary open-angle glaucoma (POAG) is the most common
type of glaucoma, a group of diseases that affect approximately 60
million people worldwide and is a leading cause of blindness [1].
Glaucoma is characterized by the progressive death of retinal
ganglion cells, leading to optic nerve atrophy and loss of vision.
POAG is a complex inherited disorder for which an increasing
number of genetic associations have been described, each
contributing modestly to disease burden [2,3].
A recent POAG genome-wide association study found a
significant genetic association (rs10483727, odds ratio (OR)= 1.32,
p=3.87610211) at the SIX1/SIX6 locus [4]. Variants in the SIX1/
SIX6 locus were first associated with quantitative optic nerve
parameters in controls, including vertical cup-disc ratio (VCDR),
which is used clinically to diagnose and monitor POAG progression
[5,6]. Several studies have independently confirmed the association
of the SIX1/SIX6 locus with both VCDR and POAG [7–9].
The human SIX gene family consists of six members (SIX1–
SIX6), all of which contain two shared protein domains; a DNA
binding homeobox domain and a SIX domain, which binds
downstream effector molecules [10,11]. Members of this con-
served gene family were originally identified through homology to
the Drosophila melanogaster (Drosophila) sine oculis (so) gene, which is
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required for proper eye development [10,11] and are thought to
function as transcription factors, regulating key developmental
steps through a complex regulatory network. During embryonic
development, SIX1 is expressed broadly in multiple tissues,
including the otic vesicle and the limb mesenchyme. However,
expression of SIX6 is restricted to regions of the retina and the
pituitary [10,12]. Drosophila with null so alleles have restricted
retinal development, while morpholino knockdown of six6b in
Danio rerio (zebrafish) embryos was recently shown to result in a
small eye phenotype [10,13]. In humans, a large deletion on
chromosome 14q22.3-q23 that includes SIX6 causes bilateral
anophthalmia, the absence of both eyes, demonstrating the
importance of SIX gene family members in ocular development
and human disease [10,11,14–16].
In this study, we have extended the current understanding of the
molecular contributions of SIX6 to POAG risk. First, we identified
potential POAG risk alleles by sequencing the SIX6 gene in a case-
control dataset; we found both common and rare coding changes
within SIX6 in POAG cases, as well as sequence variants in the
SIX6 enhancer. We then used the zebrafish system to demonstrate
that these human coding variants have functional consequences in
eye development. This analysis of 2–3 day old zebrafish embryos is
not intended to fully recapitulate the glaucomatous phenotype;
however, it provides in vivo data about the functional effects of
human genetic variation on the human SIX6 protein in the
context of eye development. We next used luciferase reporter
assays, through which we show that a sequence variant found in
the SIX6 enhancer of POAG patients may increase SIX6
expression. Finally, we demonstrate that POAG cases homozygous
for the SIX6 risk allele rs33912345 have a significantly thinner
retinal nerve fiber layer, suggesting a glaucomatous pathogenic
mechanism driven by SIX6 dysfunction.
Results
Identification of SIX6 risk alleles in POAG cases
Sequencing of the SIX1 and SIX6 genes in Caucasian POAG
cases and controls (262 cases, 256 controls) revealed 23 SNPs
(Supplemental Table S1). Nine SNPs were identified in SIX1, but
no nonsynonymous SNPs were present in the POAG cases.
Sequencing of SIX6 yielded 14 variants including five rare
nonsynonymous SNPs in POAG cases and controls, one common
nonsynonymous SNP located in the homeobox of SIX6
(rs33912345, Asn141His), and five sequence variants within the
SIX6 enhancer. All of these variants are conserved evolutionarily
as shown by their positive Genomic Evolution Rate Profiling
(GERP) scores (Table 1) [17].
Genotyping of rs33912345 in the Duke POAG case-control
dataset (482 cases, 433 controls) resulted in a significant association
(OR=1.40, p = 0.0005, POAG case minor allele frequency
(MAF) = 0.47, POAG control MAF=0.38) with POAG. This
SNP is in high linkage disequilibrium (r2 = 0.95) with the
intergenic SNP identified originally in POAG and VCDR
genome-wide association studies (rs10483727) [4–6,13]. As
expected, meta-analysis of the imputed genotype data from the
NEIGHBOR and GLAUGEN studies confirmed a significant
association between POAG status and rs33912345 (OR=1.27,
p = 4.2610210) and other linked SNPs in the region (Supplemental
Table S2). Further examination of this locus showed that the
association signal includes both upstream and downstream regions
of the SIX6 transcript, while remaining entirely downstream of
SIX1 (Supplemental Figure S1).
We next performed optical coherence tomography (OCT) to
study the retinal characteristics of POAG cases possessing the SIX6
risk and non-risk variants (Table 2). OCT images were only
available for POAG cases with the common SNP, rs33912345; no
data were available for individuals with the rare SIX6 variants. We
assessed retinal nerve fiber layer (RNFL) thickness in thirty POAG
cases homozygous for the rs33912345 risk allele (C) or the non-risk
allele (A) first by comparing age at disease diagnosis and age at
OCT across the two genotypes, because age is known to influence
retinal thickness and is thus a potential confounder. We observed
no significant difference in age (p = 0.11, p= 0.14, respectively).
Next, RNFL thickness was evaluated. The overall thickness (global
RNFL) was reduced significantly in cases homozygous for the risk
allele compared to cases with the non-risk allele (p = 0.03; mean
(SD): C= 58.3 (8.2) mm, A=67.9 (12.4) mm; Table 2), consistent
with the hypothesis that SIX6 may increase POAG susceptibility
via changes in the neural retina. To determine which quadrants
might be driving this observation, we performed an exploratory,
post-hoc comparison of RNFL thickness in the temporal, nasal,
inferior, and superior regions. We found that RNFL thickness was
reduced significantly in the inferior (p = 0.03) and superior
(p = 0.04) quadrants, the two regions affecting directly VCDR
measurements.
In vivo functional interrogation of SIX6 missense variants
Given 1) the observed association signal pattern; 2) the lack of
coding changes identified in SIX1; 3) the presence of rare missense
variants and a common, associated missense SNP in SIX6; 4)
retinal nerve fiber layer thickness changes observed in POAG
cases homozygous for the SIX6 risk allele; and 5) the localized
expression of SIX6 in ocular tissues, we concluded SIX6 is a likely
candidate gene in this region. We therefore evaluated the
functional relevance of SIX6 and the potential burden of common
and rare alleles in this locus in POAG using an in vivo zebrafish
complementation assay.
First, we performed a reciprocal BLAST analysis; we identified
two orthologs of SIX6 in the zebrafish genome, Six6a and Six6b,
both with 91% homology at the protein level (Supplemental
Figure S2). Previous overexpression and loss of function studies of
Six6 in Mus musculus (mouse) and Xenopus laevis (Xenopus) models
reveal a role in regulating the proliferative state of retinal
progenitor cells and the size of the eye [18,19]; therefore, as a
first test of whether the identified SIX6 variants are pathogenic and
Author Summary
Primary open angle glaucoma is a blinding disease for
which there is currently no cure, only treatments that may
slow its progress. To help understand the mechanisms of
this disease and to design more effective treatments, we
identified previously a locus, SIX6, that increases the risk of
glaucoma. This gene is involved in early eye development
and helps to form the retina. In this paper, we test specific
sequence variants in SIX6 that are found in glaucoma
patients. We show that these variants have a reduced
function that interferes with their ability to direct proper
formation of the retina. One variant in particular is
common, and may be the main reason that this gene is
important in the glaucoma disease process. Patients who
have two copies of this sequence variant show a change in
the structure of their eye consistent with fewer neurons
that carry the visual signal to the brain. These neurons
typically die as people age, and people who begin life with
fewer visual neurons may have an increased risk of
glaucoma. Additional research in this topic may lead to
new treatments that preserve sight.
Functional Annotation of SIX6 in Glaucoma
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potentially relevant to POAG, we asked whether 1) morpholino-
induced suppression of six6a or six6b leads to a reduced eye size; 2)
expression of the human SIX6 non-risk allele rescues the morphant
eye phenotype; and 3) expression of SIX6 alleles containing POAG
risk variants rescues the morphant eye phenotype.
Using translation-blocking morpholinos (MOs) targeting zebra-
fish six6a and six6b, we injected 1–8 cell stage embryos (N=50–
150) and analyzed live embryos at 3 days post fertilization (dpf).
We also tested a splice blocking MO. However, this induced non-
specific toxicity, including the accumulation of pericardial fluid
that could not be rescued with the human SIX6 transcript. This is
not unexpected, as SIX6 is a two exon gene—splice-blocking MOs
are generally not recommended for two exon genes; the targeted
transcript will not be subject to nonsense mediated decay, possibly
leading to the expression of a truncated protein and potential
dominant-negative effects (described by the manufacturer: http://
www.gene-tools.com/node/18). For these reasons, we used
translation-blocking MOs for the remainder of our experiments.
Masked scoring of both six6a and six6b morphants revealed ocular
phenotypes consistent with loss of function, including a reduction
in eye size in more than 80% of embryos (p,0.001, Figure 1). The
specificity of the MO was tested by co-injection of 12.5 pg of the
human SIX6 non-risk allele mRNA; we observed significant (p,
0.001) rescue in six6a but not six6b morphant embryos (90% vs.
10% of embryos, respectively). Together, these data indicate that
Six6a is the functional ortholog of human SIX6 and prompted
subsequent evaluation of SIX6 variants using the six6a MO.
To investigate the pathogenic potential of all SIX6 variants, we
used total eye size and the rescue of the morphant phenotype as
the assay’s phenotypic readout. We injected a mixture containing
six6a MO and each of the human SIX6 alleles containing the
coding variants identified via sequencing (Table 1). Subsequent to
triplicate injections and masked scoring, these results were
compared to the rescue condition of the human SIX6 non-risk
allele. We found that five of the six variants tested were unable to
fully rescue the small eye phenotype. Four of these alleles
(Glu129Lys, Asn141His, Thr212Met, and Ser242Ile) resulted in
an average eye size larger than the morpholino alone (p,0.001),
but smaller than the rescue with the non-risk allele (p,0.001),
indicating that these alleles are hypomorphic (Figure 2, Table 3).
We also observed one variant (Leu205Arg) with an average eye
size smaller than the morpholino alone (p = 0.002; mean (SD):
MO=34,042 (5,763) mm2, Leu205Arg = 31,568 (6,485) mm2;
Figure 2), suggesting that it is functionally null. Finally, one allele
(Glu93Gln) resulted in an eye size similar to the rescue with the
non-risk allele (p = 0.37) and was determined to be benign. The
benign allele was identified in one control individual, while the
remaining hypomorphic and null alleles were identified either
exclusively or primarily in POAG cases (Table 1). Injection of
12.5 pg of the human SIX6 risk mRNA into non-morphant
zebrafish provided no evidence of a toxic gain of function
compared to injection with the non-risk allele (data not shown).
Given the reduction of the RNFL in cases homozygous for the
risk allele, we next asked whether six6a and the identified SIX6
variants impacted the optic nerve, an anatomical site directly
relevant to human POAG, in zebrafish. Using whole mount
imaging of acetylated-tubulin expression in 2-dpf embryos injected
with a control and six6a morpholino, we evaluated volumetric
regions of interest (ROI) along the optic nerve (Supplemental
Figure S3). Masked scoring of embryos revealed an approximately
3 fold reduction (p,0.001) in the volume of the optic nerve upon
depletion of six6a (Figure 3 A–B). This was specific for the optic
nerve as the volume of other axonal tracts in the brain were
unaffected by six6a depletion (Figure 3A). Specificity of the
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volumetric measurements was demonstrated upon full rescue of
the six6a morphant phenotype by co-injection of the non-risk allele
(p,0.001) or a variant that scored as a benign allele in the eye size
assay (Glu93Gln; p,0.001; Figure 3B). Both Leu205Arg and
Asn141His variants performed as hypomorphic alleles (p,0.01),
revealing concordance of our optic nerve assay with the OCT
imaging findings in patients.
In vitro functional interrogation of SIX6 enhancer variants
We hypothesized that POAG risk may be mediated not only by
deficits in SIX6 protein function, but also by the level of SIX6 gene
expression. To test this, we sequenced the SIX6 retinal specific
enhancer element in 262 POAG cases and 256 POAG controls;
we identified five variants (Chr14:60974363_C,
Chr14:60974373_T, Chr14:60974378_T, Chr14:60974400_A,
Chr14:60974449_G) (Table 1), and tested their effect on
expression using an in vitro luciferase assay. We found that one
of these variants (Chr14:60974449_G) resulted in a significant
increase in expression compared to the reference enhancer
(Figure 4). Activation of the SIX6 enhancer requires two cofactors,
NeuroD and E47 (Supplemental Figure S4) [12]. Overexpression
was observed with the Chr14:60974449_G variant even in the
absence of these cofactors (Supplemental Figure S5), suggesting
variants within the enhancer region may result in dysregulated
protein expression.
Discussion
The SIX1/SIX6 locus has been shown to be associated
significantly with POAG in several independent studies; however,
the causal variant(s) driving this association have remained
unknown [4,6–9,13], as has the direction of effect of these
common alleles on protein function. We have demonstrated
through several lines of evidence—the tissue specificity of the SIX
gene family described in the literature; the identification of SIX6
missense variants in our POAG dataset; and the results of the in
vivo and in vitro assays— that SIX6 is the most likely POAG
susceptibility gene in this region. We identified both common and
rare coding variants that alter the function of the SIX6 protein.
We also identified a novel variant within the SIX6 enhancer that
appears to disrupt the regulation of SIX6 expression, suggesting
both regulatory and coding variants may influence POAG
susceptibility at this locus. Finally, we identified hitherto unknown
clinical features in POAG patients that may be dependent upon
SIX6 genotype: patients homozygous for the SIX6 risk allele have a
significantly thinner retinal nerve fiber layer than patients
homozygous for the SIX6 non-risk allele.
The common variant, rs33912345 (Asn141His), which we
showed has significantly reduced function in an in vivo model, was
associated with POAG in our dataset and is in strong linkage
disequilibrium with the originally identified GWAS SNP,
rs10483727 [4]. This conserved amino acid is located within
the alpha helix structure of the DNA homeobox domain of SIX6.
Interestingly, the ancestral allele (C, His) is associated with
POAG risk. The allele frequency of this variant differs markedly
among populations (C allele frequency: YRI (0.99), ARF (0.96),
ASN (0.76), and CEU (0.42); from 1000 Genomes release 14)
[20]. This locus is associated significantly with an increase in
Table 2. OCT measurements from POAG cases homozygous for rs33912345.
Variable Allele N Mean (SD) p
Age at POAG diagnosis (years) A 18 63.9 (9.1) 0.11
C 12 69.7 (10.2)
Age at OCT measurement (years) A 18 71.2 (9.7) 0.13
C 12 76.9 (10.3)
Nerve fiber thickness (mm): Global A 18 67.9 (12.4) 0.03
C 12 58.3 (8.2)
Temporal A 18 57.2 (15.2) 0.85
C 12 56.2 (12.8)
Nasal A 18 57.4 (13.4) 0.06
C 12 47.9 (12.8)
Inferior A 18 79.6 (18.7) 0.03
C 12 65.2 (12.6)
Superior A 18 77.0 (22.2) 0.04
C 12 63.9 (10.8)
SD= standard deviation; OCT =optical coherence tomography.
doi:10.1371/journal.pgen.1004372.t002
Figure 1. Morpholino knockdown of six6a. Zebrafish were
microinjected with a six6a translation blocking morpholino. Lateral
images, taken 3 days post fertilization (3 dpf), of a wild-type zebrafish
(left) and a morpholino injected zebrafish (right) are shown, highlight-
ing the small eye phenotype (dashed circle).
doi:10.1371/journal.pgen.1004372.g001
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vertical cup-disc ratio (VCDR) in population controls, indicating
that it may be involved in the development of the optic nerve.
VCDR is also a clinical measure used to track disease progression
in POAG patients [5,6,9,13,21]. We note that African popula-
tions have larger VCDR and an increase in overall POAG
prevalence [22–24] compared to CEU populations; in a recent
Figure 2. In vivo zebrafish morpholino complementation assay showing the effect of SIX6 nonsynonymous variants. Zebrafish
embryos were microinjected with a translation blocking morpholino designed to target six6a. Total eye size (mm2) was measured 3 days post
fertilization. Compared to the uninjected controls, morphants showed a significant reduction in eye size. Zebrafish were co-injected with the
morpholino and a human SIX6 allele (Glu93Gln, Glu129Lys, Asn141His, Leu205Arg, Thr212Met, or Ser242IIe). Results of each allele were compared to
the SIX6 non-risk allele (Ref). P-values are provided below the mean of each treatment.
doi:10.1371/journal.pgen.1004372.g002
Table 3. Results from the in vivo zebrafish six6a morpholino complementation assay.
Treatment N Mean (SD), mm2 p
Uninjected Control 146 53,140 (4,536) ,0.0001
Translation Blocker Morpholino 153 34,042 (5,763) ,0.0001
Human SIX6 Non-risk allele 177 49,040 (11,652) Ref
Glu93Gln Variant allele 92 50,010 (5,893) 0.37
Glu129Lys Variant allele 100 44,719 (6,791) ,0.001
Asn141His Variant allele 129 43,150 (10,660) ,0.0001
Leu205Arg Variant allele 101 31,568 (6,485) ,0.0001
Thr212Met Variant allele 84 38,278 (7,244) ,0.0001
Ser242IIe Variant allele 88 38,420 (7,310) ,0.0001
N= sample size; SD = standard deviation.
doi:10.1371/journal.pgen.1004372.t003
Functional Annotation of SIX6 in Glaucoma
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study, the prevalence of POAG in Ghana exceeded 17%, the
highest rate observed anywhere in the world [25]. While
rs33912345 is not associated with POAG risk in a West African
POAG case/control dataset from Ghana, the frequency of the
ancestral (risk) allele is 99% in both cases and controls [26]. We
hypothesize that differences in the structure of the optic nerve
and the higher risk of POAG in individuals with African ancestry
may, in part, arise from the fact that essentially all individuals in
this population are homozygous for the rs33912345 ancestral risk
allele.
Given the association of the SIX6 locus with neural retinal
measurements such as VCDR, it is reasonable to hypothesize
causal variants may function by inducing quantitative changes in
cell populations in the retina. There is extensive evidence that
SIX6 regulates early retinal progenitor cell proliferation during
eye development [18,19,27]. Li et al. showed that Six62/2 mice
display varying degrees of retinal hypoplasia that is due to a
decrease in retinal ganglion cell proliferation arising from an
early exit from the cell cycle during development, and results in
a 20% decrease in the number of retinal ganglion cells by P35
[18]. This is consistent with functional studies of XOptx2, the
Xenopus ortholog of SIX6 [19]. We have shown a reduction in eye
size and in the volume of the optic nerve upon MO knockdown
of zebrafish six6a, and we were able to rescue these phenotypes
with co-injection of the human SIX6 non-risk allele, demon-
strating that the zebrafish six6a gene is the likely functional
ortholog to human SIX6. We identified five alleles that could not
rescue the small eye and optic nerve phenotypes, and we
observed a reduction in retinal nerve fiber layer thickness in
POAG patients homozygous for the His141 SIX6 risk allele.
Taken together with previously published findings, our results
suggest that risk variants in human SIX6 increase POAG
susceptibility by negatively affecting retinal ganglion cell
development, likely leading to a reduction in the number of
Figure 3. Functional evaluation of SIX6 variants on the volume of the optic nerve. Representative whole mount images of acetylated-
tubulin expression in the heads of zebrafish embryos injected with a control or six6a morpholino, rescued by co-injection with human non-risk SIX6
transcript or a transcript containing the Leu205Arg hypomorphic variant (A). Acetylated-tubulin staining is restricted primarily to axon tracts and can
be used to visualize the optic nerve. Relative to the control morphants, volumetric regions of interest (ROI) along the optic nerve in six6a morphants
were reduced significantly. Co-injection of human variants revealed a hypomorphic (Leu205Arg, Asn141His) or benign (Glu93Gln) role of the variants
on the optic nerve (B). Sample size for all injection paradigms ranged from 7–9 and p-values are plotted for each comparison (*** p,0.001; ** p,
0.01). No significant changes in the volume of other axonal tracts in the head (marked by an asterisk) were detected. Standard error of the mean is
shown and white scale bars = 20 um.
doi:10.1371/journal.pgen.1004372.g003
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retinal ganglion cells in adulthood. Given that retinal ganglion
cells are lost during the normal aging process, we speculate that
this rate of loss could be increased by the presence of additional
POAG risk alleles or other risk factors such as increased
intraocular pressure [28]. The development of glaucomatous
optic neuropathy and associated visual field loss would thus be
hastened by a reduction in the initial number of retinal ganglion
cells that an individual possesses. Future work will test the
possibility that SIX6 variants also alter the rate of RGC death in
the adult.
In summary, we have identified multiple common and rare
SIX6 sequence variants in POAG cases, and used in vivo and in vitro
assays to demonstrate that these variants have functional
consequences on SIX6 expression and protein function. While
other risk factors may be required for the onset of POAG, our data
suggest that attenuation of SIX6 protein function increases an
individual’s susceptibility to developing the disease via changes to
retinal development. Additional work is needed, possibly through
the use of transgenic animal model studies, to fully understand the
role of SIX6 in POAG.
Figure 4. In vitro luciferase assay results showing the effect of SIX6 enhancer variants. SIX6 enhancer alleles were tested using a dual
luciferase assay and the ratio of the experimental luciferase: control luciferase was calculated (DLR ratio). All vectors were co-transfected with NeuroD
and E47. In this context, the SIX6 enhancer is functioning to increase expression compared to the empty vector (pGL4.23), driven by a minimal
promoter. Compared to the reference enhancer (Ref), one variant (Chr14:60974449_G) significantly increases the enhancer’s activity.
doi:10.1371/journal.pgen.1004372.g004
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Materials and Methods
Ethics statement
This research was approved by the Institutional Review Board
of Duke University Medical Center and adheres to the tenets of
the Declaration of Helsinki.
Subjects
Study subjects were unrelated patients from the Duke Eye
Center and, after a comprehensive eye examine, were classified as
either POAG cases or controls. POAG cases presented with
glaucomatous optic neuropathy, defined as a cup-to-disc ratio
greater than 0.7 and visual field loss in at least one eye. Patients
with secondary forms of glaucoma or a history of ocular trauma
were excluded from the study. POAG controls had no evidence of
optic neuropathy, normal intraocular pressure (less than
22 mmHg in both eyes), and normal visual fields, assessed using
standard automated perimetry.
DNA sequencing
Genomic DNA was extracted from patient blood samples using
the PureGene chemistry following the manufacturer’s standard
protocol (Gentra, Minneapolis, MN). The coding portions (2
exons) of the SIX1 and SIX6 genes were sequenced in 518
Caucasian POAG cases and controls (262 cases, 256 controls)
using a polymerase chain-reaction (PCR) containing 16Qiagen
PCR buffer (Tris?Cl, KCl, (NH4)2SO4, 15 mM MgCl2; pH 8.7);
200 mM each of dATP, dCTP, dGTP, and dTTP; 0.4 mM
forward PCR primer; 0.4 mM reverse PCR primer; 3 mL of
betaine, 10 ng genomic DNA; and 0.5 U HotStarTaq DNA
polymerase (Qiagen, Venlo, Limburg) to a final volume of 25 mL.
Primer sequences are available in Supplemental Table S3. The
PCR was performed using a touchdown protocol (incremental
lowering of annealing temperature) using the following thermo-
cycler conditions: 94uC for 30 s, 65uC for 30 s, 72uC for 30 s with
a 2uC decrease in the annealing temperature every two cycles until
a final annealing temperature of 55uC was reached. The retinal
specific SIX6 enhancer, previously described [12], was amplified a
using a touchdown protocol with a final annealing temperature of
57uC. PCR products were sequencing using the BigDye chemistry
on a 3730 DNA Analyzer (Applied Biosystems, Grand Island,
NY).
Genotyping and imputation
The common missense single nucleotide polymorphism (SNP),
rs33912345, was genotyped in the Duke POAG case-control
dataset consisting of 482 POAG cases and 433 POAG controls
using a TaqMan allelic discrimination assay according to the
standard protocols from the manufacturer (Life Technologies,
Grand Island, NY). For quality control purposes the following
criteria were met: .95% genotyping efficiency, matching sample
duplicates (two Centre d’Etude du Polymorphisme Humain
samples per 96-well plate whose genotype data matched across
all plates), and Hardy-Weinberg equilibrium assumptions. We
tested for association of rs33912345 with POAG using an additive
logistic regression model adjusted for age and sex using SAS [29].
Genome-wide genotype data were available from the NEI
Glaucoma Human Genetics Collaboration (NEIGHBOR) and the
Glaucoma Genes and Environment (GLAUGEN) consortia [4].
Chromosome 14 was imputed using IMPUTE2 (http://mathgen.
stats.ox.ac.uk/impute/impute_v2.html) with a global 1000 Ge-
nomes reference panel. We tested SNPs at the SIX1/SIX6 locus for
association with POAG using an additive logistic regression
model adjusted for age, sex, and four principal components
(NEIGHBOR) or age, gender, study site, DNA extraction method,
DNA specimen type and principal components 1–6 (GLAUGEN)
implemented in PLINK and visualized using LocusZoom (http://
csg.sph.umich.edu/locuszoom/) [30,31]. A meta-analysis was
performed in Plink using a random effects model. Linkage
disequilibrium was calculated and visualized using Haploview
(http://www.broadinstitute.org/scientific-community/science/
programs/medical-and-population-genetics/haploview/haploview)
[32].
Retinal nerve fiber layer thickness analysis
Optical coherence tomography (OCT) measurements of retinal
nerve fiber layer (RNFL) by Spectralis (Heidelberg Engineering,
Carlsbad, CA) spectral domain) and fundus photography were
available from the Duke Eye Center. OCT images are not
routinely performed in patients without ocular disease, so there
was limited data available for controls. Therefore, the analysis was
restricted to POAG cases homozygous for rs33912345. Thirty
patients had both OCT measurements and SIX6 genotype data.
RNFL thickness, age at POAG diagnosis, and the age at OCT
measurement were compared between individuals homozygous for
the risk or non-risk allele using a Student’s t-test. Analyses were
performed in SAS [29].
Microinjection of morpholino and mRNA
A vector containing human SIX6 was purchased from the
CCSB Human ORFeome Collection that uses the Gateway
technology system (Open Biosystems and Life Technologies,
Grand Island, NY). SIX6 alleles identified by sequencing
(Glu93Gln, Glu129Lys, Asn141His, Leu205Arg, Thr212Met,
Ser242IIe), were created using the QuikChange II site-directed
mutagenesis kit and protocols provided by the manufacturer
(Agilent Technologies). SIX6 mRNA was in vitro transcribed
using mMESSAGE mMACHINE SP6 Kit (Ambion, Life
Technologies, Grand Island, NY). Translation blocker (TB)
morpholinos against six6a (59- CTGGAACATGGAGACTG-
TAATGTCT -39) and six6b (59 AATTGGCAACTGAAACAT-
GAAGGCT 39) were purchased from Gene Tools, LLC.
Morpholino (2 ng) and mRNA (12.5 pg) were mixed and a
volume of 0.5 nL was microinjected into each wild-type
zebrafish embryo at one- to eight-cell stage as described
previously (Stuart, McMurray et al. 1988).
Morphometric analyses of zebrafish
Morphometric analyses of eye size were conducted on zebrafish
embryos at 3 days post fertilization, using a Nikon SMZ 745T
microscope. Zebrafish were anesthetized in embryo medium
containing 0.2 mg/ml tricaine (Ethyl 3-aminobenzoate methane-
sulfonate, Sigma, E10521). Lateral view images were captured
with Nikon DS-Fi1 camera, and the size of eye was measured with
Nikon NIS-Elements AR software. Analysis of the optic nerve was
performed on 2 dpf embryos fixed in Dent’s fixative (80%
Methanol and 20% DMSO) overnight and stained with acetylat-
ed-tubulin (Sigma; T7451). Heads were isolated from stained
embryos and oriented with the ventral aspect facing a coverslip on
microscope cover glass. Image acquisition was performed on a
Zeiss 710 inverted confocal microscope and ,100 um optical
sections were obtained and reconstructed. Volumetric measure-
ments were calculated using Imaris software and 7.5 um67.5 u-
m615 um ROIs along the optic nerve were analyzed between
each condition. ROIs were restricted to portions of the optic nerve
wherein all neurite processes coalesced to form the major aspect of
the nerve.
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In vitro luciferase assay
SIX6 enhancer alleles were tested using the dual-luciferase
reporter assay system (Promega, Madison, WI). An experimental
construct containing a minimal promoter (pGL4.23, firefly
luciferase, Promega) was used to test the functional effect of the
enhancer alleles identified by sequencing (Chr14:60974363_C,
Chr14:60974373_T, Chr14:60974378_T, Chr14:60974400_A,
Chr14:60974449_G) in the POAG case/control dataset.
The experimental constructs (pGL4.23+Enhancer) were
generated using a nested PCR protocol; the XhoI and
HindII enzymes; the Quick Ligation kit (New England
BioLabs, Ipswich, MA); and the QuikChange II site-
directed mutagenesis kit (Agilent Technologies), following
protocols provided by the manufacturers. Constructs were
confirmed to be correct by sequencing. Hek293 cells were
cultured according to the supplier’s suggestions (ATCC,
Manassas, VA). As described by Conte et al., co-transfection
with NeuroD and E47 is required for SIX6 enhancer activation
[12]. Therefore, cells were co-transfected with an experimental
vector (pGL4.23+Enhancer), a control vector (pGL4.74, renilla
luciferase, Promega), and vectors containing NeuroD and E47
(provided by the Center for Human Disease Modeling, Duke
University) using a standard calcium phosphate transfection
protocol. The experiment was performed three times in triplicate
and the results were analyzed using the dual luciferase reporter
(DLR) ratio (firefly luciferase sum: renilla luciferase sum)
normalized by the reference SIX6 enhancer included on
every plate. The data were analyzed using an ANOVA, adjusted
for batch, and linear contrasts were used to determine the
effect of each vector. Statistical analyses were performed in SAS
[29].
Supporting Information
Figure S1 Plot of the association signal from the NEIGHBOR
and GLAUGEN POAG meta-analysis results observed at the
SIX1/SIX6 locus calculated using chromosome 14 imputed
genotype data. Generated using LocusZoom (http://genome.
sph.umich.edu/wiki/LocusZoom). The color indicates the r2 value
with the index SNP, rs10483727.
(TIF)
Figure S2 Results from BLAST search showing homology
between human SIX6 and zebrafish Six6a and Six6b. The
human SIX6 protein shares 91% identity with both of
the zebrafish orthologs, Six6a and Six6b. Red: conserved across
all proteins; Blue: conserved across 2 proteins; Grey: not
conserved.
(TIF)
Figure S3 Volumetric analysis of the optic nerve. Confocal
image of a 2 dpf zebrafish head stained with antibody to acetylated
tubulin to visualize axons. (A) Regions of Interest (ROIs)
7.5 um67.5 um615 um in size along the optic nerve were
selected from reconstructed 3-dimensional images using Imaris
software [X–Y plane (B–C) and X–Z plane (D–E)]. Panels C and
E show the reconstructed ROI from which volumetric measure-
ments are calculated.
(TIF)
Figure S4 In vitro luciferase assay results from the SIX6
enhancer and co-transfection with NeuroD and E47. The SIX6
enhancer alone was inactive compared to the empty vector
(pGL4.23). Co-transfection of both NeuroD and E47 increased
the enhancer’s activity. The highest activity level was reach with
co-transfection of an equal amount of both, as previously
described [12].
(PDF)
Figure S5 In vitro luciferase assay results showing the effect of the
SIX6 enhancer without co-transfection of NeuroD and E47. SIX6
enhancer alleles were tested using a dual luciferase assay and the
ratio of the experimental luciferase: control luciferase was
calculated (DLR ratio). In the absence of NeuroD and E47, the
SIX6 enhancer is not active. However, the Chr14:60974449_G
variant still shows increased enhancer activity. Coordinates are
based on the Hg19 reference. P-values are provided below the
mean of each vector.
(PDF)
Table S1 Coding variants identified by sequencing SIX1 and
SIX6 in 518 POAG cases and controls. Coordinates are based on
the Hg19 reference.
(DOCX)
Table S2 Top SNPs from the imputed Chromosome 14 POAG
association analysis. Plink output from meta-analysis of the
NEIGHBOR and GLAUGEN logistic regression results. OR= -
odds ratio.
(DOCX)
Table S3 Primer sequences used in this study.
(DOCX)
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